Menu
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Outset investments or would like to inquire about potentially pursuing Jetzt den vollständigen Artikel lesen
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or “the Company”) (NASDAQ: OM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Jetzt den vollständigen Artikel lesen
Law Offices of Howard G. Smith continues its investigation on behalf of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors concerning the Company’s possible violations of federal securities laws. On August 7, 2024, Outset Medical released its second quarter 2024 financial results, significantly missing consensus estimates and lowering its full year 2024 outlook. Jetzt den vollständigen Artikel lesen
The Law Offices of Frank R. Cruz continues its investigation of Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) on behalf of investors concerning the Company’s possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 7, 2024, Outset Medical released its second quarter 2024 financial results, Jetzt den vollständigen Artikel lesen
Outset Medical (OM) stock plunges 64% on missed Q2 estimates and lowered revenue outlook, leading to RBC Capital Markets to downgrade. Read more here.
https://www.investing.com/news/stock-market-news/earnings-call-outset-medical-reports-disappointing-earnings-in-secondquarter-93CH-3562579
Datadog (NASDAQ: DDOG ) stock is heading higher on Thursday following the release of the cloud applications security platform company’s earnings report for the second quarter of 2024. Datadog starts off its earnings report strong today with adjusted EPS of 43 cents . That’s better than the 36 cents per share that Wall Street was expecting this quarter. Additionally, it’s an improvement over the 29 cents per share reported in the same period of the year prior. Next up in the Datadog earnings report is its revenue of $645 million. Yet again, that’s above analysts’ estimate of $625.1 million for the period. It’s also a 27% year-over-year increase compared to $509.46 million. Olivier Pomel, co-founder and CEO of Datadog, saif the following in the earnings report. “Datadog executed well in the second quarter, with 27% year-over-year revenue growth, continued customer growth, and expanding multi-product adoption across our platform.” DDOG Stock Jumps on Outlook Datadog also provides new guidance for Q3 2024 and the full year.
Outset Medical Inc (OM) Q2 2024 Earnings Call Transcript Highlights: Key Takeaways and Strategic Adjustments
SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Outset Medical, Inc. (NASDAQ: OM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.
